Candel Therapeutics (CADL) Common Equity (2020 - 2023)
Historic Common Equity for Candel Therapeutics (CADL) over the last 4 years, with Q3 2023 value amounting to $23.0 million.
- Candel Therapeutics' Common Equity fell 5583.48% to $23.0 million in Q3 2023 from the same period last year, while for Sep 2023 it was $23.0 million, marking a year-over-year decrease of 5583.48%. This contributed to the annual value of $47.7 million for FY2022, which is 2560.61% down from last year.
- As of Q3 2023, Candel Therapeutics' Common Equity stood at $23.0 million, which was down 5583.48% from $30.8 million recorded in Q2 2023.
- Candel Therapeutics' 5-year Common Equity high stood at $64.1 million for Q4 2021, and its period low was -$43.2 million during Q2 2021.
- Over the past 4 years, Candel Therapeutics' median Common Equity value was $47.7 million (recorded in 2022), while the average stood at $34.3 million.
- Per our database at Business Quant, Candel Therapeutics' Common Equity skyrocketed by 37220.52% in 2021 and then plummeted by 5583.48% in 2023.
- Candel Therapeutics' Common Equity (Quarter) stood at -$23.6 million in 2020, then surged by 372.21% to $64.1 million in 2021, then dropped by 25.61% to $47.7 million in 2022, then plummeted by 51.75% to $23.0 million in 2023.
- Its last three reported values are $23.0 million in Q3 2023, $30.8 million for Q2 2023, and $39.7 million during Q1 2023.